
# Title 21 - Food and Drugs
## Chapter I - Food and Drug Administration, Department of Health and Human Services
### Subchapter D - Drugs for Human Use
#### PART 312 - INVESTIGATIONAL NEW DRUG APPLICATION
##### Subpart I - Expanded Access to Investigational Drugs for Treatment Use
###### ยง 312.310 Individual patients, including for emergency use.
####### Safeguards.

(c)(1) Treatment is generally limited to a single course of therapy for a specified duration unless FDA expressly authorizes multiple courses or chronic therapy.

(2) At the conclusion of treatment, the licensed physician or sponsor must provide FDA with a written summary of the results of the expanded access use, including adverse effects.

(3) FDA may require sponsors to monitor an individual patient expanded access use if the use is for an extended duration.

(4) When a significant number of similar individual patient expanded access requests have been submitted, FDA may ask the sponsor to submit an IND or protocol for the use under ยง 312.315 or ยง 312.320.
